Study of Etoposide in Treating Patients With Recurrent or Metastatic Breast Cancer

Summary

The purpose of this study is to determine whether Etoposide Monotherapy is effective and safe in the treatment of recurrent or metastatic breast cancer in Chinese female patients.

Conditions

• Breast Cancer

Interventions

DRUG

Etoposide

Lastet (Etoposide Capsules, 25mg\*40 capsules/box), manufactured by Nippon Kayaku Co., Ltd.

Sponsors & Collaborators

• Peking University Cancer Hospital & Institute

  collaborator OTHER

• Peking Union Medical College Hospital

  collaborator OTHER

• Beijing Chao Yang Hospital

  collaborator OTHER

• China-Japan Friendship Hospital

  collaborator OTHER

• Beijing Hospital of the Ministry of Health

  collaborator UNKNOWN

• The First Affiliated Hospital of Dalian Medical University

  collaborator OTHER

• The Second Affiliated Hospital of Harbin Medical University

  collaborator OTHER

• Zhejiang Cancer Hospital

  collaborator OTHER

• Henan Cancer Hospital

  collaborator OTHER_GOV

• Guangxi Cancer Hospital

  collaborator UNKNOWN

• Shanghai Putuo District Center Hospital

  collaborator OTHER

• International Peace Maternity and Child Health Hospital

  collaborator OTHER

• Xinjiang Medical University

  collaborator OTHER

• Chinese Academy of Medical Sciences

  lead OTHER

Principal Investigators

• Binghe Xu, M.D., Ph.D · Chinese Academy of Medical Sciences

Study Design

Allocation

NA

Purpose

TREATMENT

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

18 Years

Max Age

80 Years

Sex

FEMALE

Healthy Volunteers

No

Timeline & Regulatory

Start

2011-12-31

Primary Completion

2014-06-30

Completion

2015-06-30

Countries

• China

Study Locations